Liquidia (LQDA) Cash from Operations Growth (1y) (2021 - 2026)
Liquidia (LQDA) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | 303.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 303.25% |
| Mar 31, 2026 | 272.72% |
| Dec 31, 2025 | 312.58% |
| Sep 30, 2025 | 61.05% |
| Jun 30, 2025 | -74.22% |
| Mar 31, 2025 | -23.38% |
| Dec 31, 2024 | -30.23% |
| Sep 30, 2024 | -116.95% |
| Jun 30, 2024 | -307.28% |
| Mar 31, 2024 | -194.03% |
| Dec 31, 2023 | -247.21% |
| Sep 30, 2023 | -100.23% |
| Jun 30, 2023 | 33.99% |
| Mar 31, 2023 | 13.55% |
| Dec 31, 2022 | 39.11% |
| Sep 30, 2022 | 0.98% |
| Jun 30, 2022 | -2.06% |
| Mar 31, 2022 | 21.02% |
| Dec 31, 2021 | 46.34% |
| Sep 30, 2021 | 53.39% |